Gateway Investment Advisers LLC Reduces Position in Avantor, Inc. (NYSE:AVTR)

Gateway Investment Advisers LLC decreased its position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 45.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 111,662 shares of the company's stock after selling 91,360 shares during the period. Gateway Investment Advisers LLC's holdings in Avantor were worth $2,353,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. grew its holdings in shares of Avantor by 2.1% during the third quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company's stock worth $644,000 after buying an additional 503 shares during the last quarter. Intech Investment Management LLC lifted its position in Avantor by 1.8% during the 2nd quarter. Intech Investment Management LLC now owns 29,068 shares of the company's stock worth $616,000 after acquiring an additional 514 shares during the period. Veracity Capital LLC grew its stake in shares of Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company's stock valued at $1,355,000 after purchasing an additional 543 shares during the last quarter. US Bancorp DE increased its holdings in shares of Avantor by 6.2% in the third quarter. US Bancorp DE now owns 12,615 shares of the company's stock valued at $326,000 after purchasing an additional 734 shares during the period. Finally, Atria Investments Inc raised its stake in shares of Avantor by 4.8% during the third quarter. Atria Investments Inc now owns 15,925 shares of the company's stock worth $412,000 after purchasing an additional 734 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AVTR shares. Barclays lowered their price objective on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, October 25th. Robert W. Baird lowered their target price on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a report on Monday, October 28th. UBS Group reissued a "neutral" rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday. Royal Bank of Canada restated an "outperform" rating and issued a $34.00 price objective on shares of Avantor in a research report on Thursday, September 26th. Finally, Wells Fargo & Company dropped their target price on Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.38.

Avantor Price Performance

AVTR traded down $0.43 during trading on Friday, reaching $22.14. 6,042,606 shares of the stock were exchanged, compared to its average volume of 3,101,021. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00. The company has a market capitalization of $15.07 billion, a price-to-earnings ratio of 48.13, a P/E/G ratio of 3.42 and a beta of 1.28. The business's 50 day moving average price is $21.45 and its two-hundred day moving average price is $23.35. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.